Aeon Astra

Aeon Astra is a biotechnology company focused on developing novel therapeutics to treat age-related diseases by targeting cellular senescence. A spin-out from the University of Oxford and Newcastle University, the company leverages deep expertise in the biology of aging to identify and develop small molecule senolytics and senomorphics. Their approach aims to selectively eliminate or modulate senescent cells that accumulate with age and contribute to chronic inflammation and tissue dysfunction. The company's platform focuses on the metabolic regulation of the senescence-associated secretory phenotype (SASP). Aeon Astra's pipeline is currently in the pre-clinical stage, targeting indications such as fibrosis and metabolic disorders. The company is backed by Oxford Science Enterprises and aims to translate fundamental aging research into clinical interventions.